[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536145":3},{"organization":4,"outcomesModule":7,"designInfo":37,"detailedDescription":48,"studyPopulation":42,"armGroups":49,"interventions":64,"overallOfficials":87,"centralContacts":91,"locations":98,"responsibleParty":128,"collaborators":42,"id":130,"slug":42,"hasResults":131,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":42,"eligibilityCriteria":135,"healthyVolunteers":131,"sex":136,"minAge":137,"maxAge":42,"enrollmentInfo":138,"targetDuration":42,"studyType":141,"phases":142,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":101,"whyStopped":42,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},{"fullName":5,"class":6},"Innovaderm Research Inc.","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":26},[9],{"measure":10,"description":11,"timeFrame":12},"Change from baseline in target lesion CLASI-A score","The CLASI-A (Cutaneous Lupus Area and Severity Index - Activity) quantifies disease activity based on scoring of erythema, scale\u002Fhypertrophy, mucous membrane involvement, acute hair loss, and non scarring alopecia.\n\nChange from baseline in target lesion CLASI-A score at Week 24 for the target DLE lesion treated with occlusion The CLASI-A score ranges from 0 to 70, with higher scores indicating more severe skin disease.","Week 24",[14,17,20,23],{"measure":10,"description":15,"timeFrame":16},"The CLASI-A (Cutaneous Lupus Area and Severity Index - Activity) quantifies disease activity based on scoring of erythema, scale\u002Fhypertrophy, mucous membrane involvement, acute hair loss, and non scarring alopecia.\n\nChange from baseline in target lesion CLASI-A score at Week 24 for the target DLE lesion treated without occlusion.\n\nThe CLASI-A score ranges from 0 to 70, with higher scores indicating more severe skin disease.","Week 12, Week 24",{"measure":18,"description":19,"timeFrame":12},"Proportion of subjects with an erythema score of 0 (absent)","Proportion of subjects with an erythema score of 0 (absent) in 50% of all DLE lesions. Erythema will be assessed for each DLE lesion identified on Day 1 using the erythema component of the CLASI-A scale. The severity of erythema is scored on a 4-point scale ranging from 0 (absent) to 3.",{"measure":21,"description":22,"timeFrame":16},"Change from baseline in target lesion SADDLE-A","Change from baseline in target lesion SADDLE-A at Week 24 for the target DLE lesion treated with and without occlusion.\n\nChange from baseline in target lesion SADDLE-A score at Week 12 for the untreated target DLE lesion and the target DLE lesion treated with and without occlusion",{"measure":24,"description":25,"timeFrame":12},"Proportion of subjects with a target lesion CLA-IGA score of 0 (clear) or 1 (almost clear)","Proportion of subjects with a CLA-IGA score of 0 (clear) or 1 (almost clear) for all DLE lesions. The CLA-IGA is a 5 point scale that evaluates the severity of signs of the overall disease activity based on erythema, scale, edema\u002F infiltration, follicular involvement, and secondary changes.",[27,31,34],{"measure":28,"description":29,"timeFrame":30},"Dermatology Life Quality Index (DLQI)","Change from baseline in DLQI. Quality of life will be evaluated using Dermatology Life Quality Index (DLQI). It is a simple 10-question validated questionnaire that has been used in more than 40 different skin conditions.The DLQI is the most frequently used instrument in studies of randomized controlled trials in dermatology.","Weeks 12 and 24",{"measure":32,"description":33,"timeFrame":30},"Cutaneous Lupus Erythematosus Quality of Life (CLEQol)","Change from baseline in CLEQoL total score.Quality of life will be evaluated using the Cutaneous Lupus Erythematosus Quality of Life (CLEQoL).The CLEQoL asks subjects to assess how often (never, rarely, sometimes, often, all the time) they experienced a given effect. Scores of 0 (never), 25 (rarely), 50 (sometimes), 75 (often), or 100 (all the time) are assigned to each question. The scores are averaged per domain from the scale of 0-100, with higher numbers indicating worse quality of life.",{"measure":35,"description":36,"timeFrame":30},"Numeric Rating Scale(NRS)","Change from baseline in target lesion pruritus NRS scores.Pruritus numeric rating scale (NRS) will also be evaluated as an efficacy assessment for each of the 2 (or 3, as applicable) target lesions.This will be evaluated by asking subjects to assign a numerical score representing worst itch intensity over the last 24 hours of each target lesion on a scale from 0 to 10, with 0 indicating no itch and 10 indicating the worst imaginable itch.",{"allocation":38,"interventionModel":39,"interventionModelDescription":40,"primaryPurpose":41,"observationalModel":42,"timePerspective":42,"maskingInfo":43},"RANDOMIZED","PARALLEL","Intra-individual","TREATMENT",null,{"masking":44,"maskingDescription":45,"whoMasked":46},"SINGLE","This study will be single-blinded. Only the efficacy assessor will be blinded in this study (for subjects with randomized areas). The assessor will only assess efficacy and will not have any other interactions with the subject.",[47],"OUTCOMES_ASSESSOR","This study is being conducted to evaluate the efficacy, safety and tolerability of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus.\n\nApproximately 20 subjects with discoid lupus erythematosus will apply ruxolitinib 1.5% cream, twice daily on active lesions identified at Day 1 and any new lesions that appear, for 24 weeks.",[50,58],{"label":51,"type":52,"description":53,"interventionNames":54},"ruxolitinib 1.5% cream (Sequence 1)","EXPERIMENTAL","ruxolitinib 1.5% cream without occlusion for Area 1 and ruxolitinib 1.5% cream under occlusion at night for Area 2",[55,56,57],"Drug: Ruxolitinib 1.5% cream","Procedure: Application without occlusion in Area 1","Procedure: Application under occlusion at night in Area 2",{"label":59,"type":52,"description":60,"interventionNames":61},"ruxolitinib 1.5% cream ( Sequence 2)","ruxolitinib 1.5% cream under occlusion at night for Area 1 and ruxolitinib 1.5% cream without occlusion for Area 2",[55,62,63],"Procedure: Application under occlusion at night in Area 1","Procedure: Application without occlusion in Area 2",[65,70,75,79,83],{"type":66,"name":67,"description":68,"armGroupLabels":69,"otherNames":42},"DRUG","Ruxolitinib 1.5% cream","Topical application of Ruxolitinib 1.5% cream",[59,51],{"type":71,"name":72,"description":73,"armGroupLabels":74,"otherNames":42},"PROCEDURE","Application without occlusion in Area 1","Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 1.",[51],{"type":71,"name":76,"description":77,"armGroupLabels":78,"otherNames":42},"Application under occlusion at night in Area 2","Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 2.",[51],{"type":71,"name":80,"description":81,"armGroupLabels":82,"otherNames":42},"Application under occlusion at night in Area 1","Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 1.",[59],{"type":71,"name":84,"description":85,"armGroupLabels":86,"otherNames":42},"Application without occlusion in Area 2","Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 2.",[59],[88],{"name":89,"affiliation":5,"role":90},"Robert Bissonnette, MD","PRINCIPAL_INVESTIGATOR",[92],{"name":93,"role":94,"phone":95,"phoneExt":96,"email":97},"Fareheen Chowdhury","CONTACT","514-521-4285","341","fchowdhury@innovaderm.com",[99,116],{"facility":100,"status":101,"city":102,"state":103,"zip":104,"country":105,"countryCode":106,"cosmosGeoPoint":107,"geoPoint":112,"contacts":113},"INNO-6051 Site 03","RECRUITING","Fredericton","New Brunswick","E3B 1G9","Canada","CA",{"type":108,"coordinates":109},"Point",[110,111],-66.66558,45.94541,{"lat":111,"lon":110},[114],{"name":115,"role":94,"phone":42,"phoneExt":42,"email":42},"Melissa Bernal",{"facility":5,"status":101,"city":117,"state":118,"zip":119,"country":105,"countryCode":106,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Montreal","Quebec","H2X 2V1",{"type":108,"coordinates":121},[122,123],-73.58781,45.50884,{"lat":123,"lon":122},[126],{"name":127,"role":94,"phone":42,"phoneExt":42,"email":42},"Lydia Edjekouane",{"type":129,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100536145",false,"NCT06261021","Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus","A Phase 2, Single-Blind, Intraindividual Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus","Inclusion Criteria:\n\n* Male or female subject 18 years of age or older at the time of consent.\n* Confirmed DLE diagnosis.\n* Subject has moderate to severe DLE, as defined by an overall CLA IGA score of 3 (moderate) or 4 (severe) at screening and Day 1.\n* Female subject of childbearing potential must have a negative urine pregnancy test at screening and negative urine pregnancy test at Day 1.\n* Subject has no known history of latent or active tuberculosis (TB) infection.\n* Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.\n* Subjects must be willing to comply with all study procedures and must be available for the duration of the study.\n\nExclusion Criteria:\n\n* Female subject who is breastfeeding, pregnant, or who is planning to become pregnant during the study.\n* Subject has a history of skin disease or presence of skin condition that would interfere with the study assessments.\n* Subject has unstable or fluctuating use of nicotine-containing products within 4 weeks prior to screening.\n* Subject is known to have immune deficiency or is immunocompromised.\n* Subject is ≥ 50 years old AND has a history of heart attack, other clinically significant heart problems, stroke, or blood clots.\n* Subject has a known history of chronic infectious disease (e.g., hepatitis B, hepatitis C, or human immunodeficiency virus \\[HIV\\]).\n* Subject is known to have hepatitis B or hepatitis C viral infection.\n* Subject has used any topical medicated treatment that could affect DLE within 2 weeks prior to Day 1, including, but not limited to, topical corticosteroids, retinoids, calcineurin inhibitors, antimicrobials, and medical devices.\n* Subject has received any marketed or investigational biological agent within 12 weeks or 5 half lives (whichever is longer) prior to Day 1, including but not limited to ustekinumab and rituximab.\n* Subject is currently receiving a nonbiological investigational product or device or has received one within 4 weeks prior to Day 1.\n* Subject has a known or suspected allergy to ruxolitinib.\n* Subject has used ruxolitinib cream (OpzeluraTM).\n* Subject has used JAK inhibitors for conditions other than DLE or other forms of lupus within 4 weeks prior to Day 1.\n* Subject has a known history of clinically significant drug or alcohol abuse in the last year prior to Day 1.","ALL","18 Years",{"count":139,"type":140},20,"ESTIMATED","INTERVENTIONAL",[143],"PHASE2","This study is a single-blind, intraindividual study to evaluate the efficacy of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus.",[146],"Discoid Lupus Erythematosus",[148,149,150],"discoid lupus erythematosus","opzelura","ruxolitinib cream","2025-03-21",{"date":153,"type":154},"2025-03-24","ACTUAL",{"date":156,"type":154},"2024-04-19",{"date":158,"type":140},"2026-02-28",{"name":5,"class":6},2]